Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BBIO 
BridgeBio Pharma Inc (BBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: BBIO (4-star) is a STRONG-BUY. BUY since 125 days. Simulated Profits (48.98%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $66.47
1 Year Target Price $66.47
| 10 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 71.37% | Avg. Invested days 38 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.37B USD | Price to earnings Ratio - | 1Y Target Price 66.47 |
Price to earnings Ratio - | 1Y Target Price 66.47 | ||
Volume (30-day avg) 19 | Beta 1.36 | 52 Weeks Range 21.72 - 57.49 | Updated Date 10/25/2025 |
52 Weeks Range 21.72 - 57.49 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.8577 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -120.72% |
Management Effectiveness
Return on Assets (TTM) -41.96% | Return on Equity (TTM) -1789.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11286931893 | Price to Sales(TTM) 43.99 |
Enterprise Value 11286931893 | Price to Sales(TTM) 43.99 | ||
Enterprise Value to Revenue 47.86 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 191168504 | Shares Floating 151434130 |
Shares Outstanding 191168504 | Shares Floating 151434130 | ||
Percent Insiders 4.77 | Percent Institutions 100.93 |
Upturn AI SWOT
BridgeBio Pharma Inc
Company Overview
History and Background
BridgeBio Pharma Inc. was founded in 2015 with the goal of discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. It has grown through internal development and strategic acquisitions.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing therapies for genetic diseases and genetically driven cancers.
Leadership and Structure
The leadership team includes Neil Kumar, Ph.D. as CEO. The company has a board of directors and operates through various functional departments like R&D, commercial, and operations.
Top Products and Market Share
Key Offerings
- Truseltiq (infigratinib): A kinase inhibitor approved for previously treated, unresectable biliary tract cancer with FGFR2 fusions or rearrangements. Its main competitors are other targeted therapies and chemotherapies used in biliary tract cancer treatment. Market share is still growing in the FGFR2-altered biliary tract cancer space.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. It is characterized by high R&D costs and long development timelines.
Positioning
BridgeBio Pharma Inc. positions itself as a leader in developing precision medicines for genetic diseases and cancers with clear genetic drivers. Their competitive advantage lies in their targeted approach and deep scientific understanding of disease mechanisms.
Total Addressable Market (TAM)
The TAM for genetic diseases and genetically driven cancers is very large, likely in the tens or hundreds of billions of dollars, given the broad range of diseases and increasing use of precision medicine. BridgeBio is positioned to capture a share of this TAM with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Strong focus on genetic diseases and cancers
- Deep understanding of disease mechanisms
- Experienced leadership team
- Strategic partnerships
- Commercial product (Truseltiq)
Weaknesses
- High R&D expenses
- Dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
- Limited number of marketed products
Opportunities
- Expanding pipeline through internal development and acquisitions
- Partnerships with leading research institutions
- Accelerated approval pathways for rare diseases
- Increasing prevalence of genetic testing
Threats
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
- Competition from new therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- ROSE (Roche Holding AG)
- MRK (Merck & Co., Inc.)
- PFE (Pfizer Inc.)
Competitive Landscape
BridgeBio competes with both large pharmaceutical companies and smaller biotech firms. Its strengths are its focus on precision medicine and its deep scientific expertise. Its weaknesses include its relatively small size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth analysis requires actual financial data and is not possible at this time.
Future Projections: Future growth projections require analyst estimates and are not possible at this time.
Recent Initiatives: Recent initiatives include advancing clinical trials, strategic partnerships, and commercialization efforts.
Summary
BridgeBio Pharma has a focused approach on genetic diseases and cancers which gives them a strong position in a niche market. While they have a commercial product, they are still dependent on clinical trial successes and face significant competition. Managing R&D costs and expanding their product pipeline will be critical. Their strategic partnerships and focus on areas with unmet medical needs may drive future growth, but regulatory hurdles and market access challenges could pose significant threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates may not be precise and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BridgeBio Pharma Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Director Dr. Neil Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 725 | Website https://bridgebio.com |
Full time employees 725 | Website https://bridgebio.com | ||
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.